These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 18806816)

  • 1. Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease.
    Grip O; Janciauskiene S; Bredberg A
    Br J Pharmacol; 2008 Dec; 155(7):1085-92. PubMed ID: 18806816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin.
    Grip O; Janciauskiene S; Lindgren S
    Inflamm Bowel Dis; 2004 May; 10(3):193-200. PubMed ID: 15290911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effects of atorvastatin on C-reactive protein induced Toll-like receptor 4 expression on CD14+ monocyte].
    Peng L; Luo YT; Liu JL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Jul; 39(7):664-9. PubMed ID: 22088250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin downregulates monocyte CD36 expression, nuclear NFkappaB and TNFalpha levels in type 2 diabetes.
    Mandosi E; Fallarino M; Gatti A; Carnovale A; Rossetti M; Lococo E; Buchetti B; Filetti S; Lenti L; Morano S
    J Atheroscler Thromb; 2010 Jun; 17(6):539-45. PubMed ID: 20134099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway.
    Li J; Li JJ; He JG; Nan JL; Guo YL; Xiong CM
    Cardiovasc Ther; 2010; 28(1):8-14. PubMed ID: 20074254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin improves plaque stability in ApoE-knockout mice by regulating chemokines and chemokine receptors.
    Nie P; Li D; Hu L; Jin S; Yu Y; Cai Z; Shao Q; Shen J; Yi J; Xiao H; Shen L; He B
    PLoS One; 2014; 9(5):e97009. PubMed ID: 24816562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo.
    Bursill CA; Castro ML; Beattie DT; Nakhla S; van der Vorst E; Heather AK; Barter PJ; Rye KA
    Arterioscler Thromb Vasc Biol; 2010 Sep; 30(9):1773-8. PubMed ID: 20702809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease.
    Grip O; Janciauskiene S
    PLoS One; 2009; 4(5):e5263. PubMed ID: 19421322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes.
    Methe H; Kim JO; Kofler S; Nabauer M; Weis M
    Arterioscler Thromb Vasc Biol; 2005 Jul; 25(7):1439-45. PubMed ID: 15860745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes.
    Grip O; Janciauskiene S; Lindgren S
    Inflamm Res; 2002 Feb; 51(2):58-62. PubMed ID: 11926313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atorvastatin restores the balance between pro-inflammatory and anti-inflammatory mediators in rats with acute myocardial infarction.
    Tawfik MK; Ghattas MH; Abo-Elmatty DM; Abdel-Aziz NA
    Eur Rev Med Pharmacol Sci; 2010 Jun; 14(6):499-506. PubMed ID: 20712256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure.
    Sola S; Mir MQ; Lerakis S; Tandon N; Khan BV
    J Am Coll Cardiol; 2006 Jan; 47(2):332-7. PubMed ID: 16412856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: evidence from a randomized controlled trial.
    Loughrey BV; McGinty A; Young IS; McCance DR; Powell LA
    Clin Endocrinol (Oxf); 2013 Dec; 79(6):800-6. PubMed ID: 23170936
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome.
    Xu ZM; Zhao SP; Li QZ; Nie S; Zhou HN
    Clin Chim Acta; 2003 Dec; 338(1-2):17-24. PubMed ID: 14637261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory signaling in pulmonary arterial hypertension: the controversial role of CRP, and the search for new therapies.
    Maciocia PM
    Cardiovasc Ther; 2010; 28(1):1-4. PubMed ID: 20074252
    [No Abstract]   [Full Text] [Related]  

  • 18. Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy.
    Lönnkvist MH; Theodorsson E; Holst M; Ljung T; Hellström PM
    Scand J Gastroenterol; 2011 Apr; 46(4):420-7. PubMed ID: 21114432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
    Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
    Mozaffarian D; Minami E; Letterer RA; Lawler RL; McDonald GB; Levy WC
    Am J Cardiol; 2005 Dec; 96(12):1699-704. PubMed ID: 16360360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.